The addition of anlotinib to toripalimab therapy potentially regulated TME and increased PD-L1 expression in tumor lesions, expanding the treatment window of toripalimab and improving the benefit of second-line therapy in GC/GEJC. Here, CD274 is linked to neoplasm.